Abstract
Patients with high bleeding risk (HBR) who undergo percutaneous coronary intervention also have an increased risk of ischemic events and represent an overall high-risk population. The coating of durable polymer drug-eluting stents (DP-DES) may induce inflammation and delay arterial healing, which might be reduced by novel biodegradable polymer DES (BP-DES). We aimed to evaluate the safety and efficacy of treating HBR patients with very thin-strut BP-DES versus thin-strut DP-DES. Participants in BIO-RESORT (NCT01674803), an investigator-initiated multicenter, randomized all-comers trial, were treated with very thin-strut BP-DES (Synergy or Orsiro) or thin-strut DP-DES (Resolute Integrity). For the present analysis, patients were classified following HBR criteria based on previous trials. The primary endpoint was target vessel failure: a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization at 1 year. Of all 3514 patients, 1009 (28.7%) had HBR. HBR patients were older (p < 0.001) and had more co-morbidities than non-HBR patients (p < 0.001). At 1-year follow-up, HBR patients had significantly higher rates of target vessel failure (6.7 vs. 4.2%, p = 0.003), cardiac death (1.9 v...Continue Reading
References
Aug 15, 1991·Annals of Internal Medicine·E G BovillC T Lambrew
Jul 4, 2006·Journal of the American College of Cardiology·Michael JonerRenu Virmani
May 2, 2007·Circulation·Donald E CutlipUNKNOWN Academic Research Consortium
Mar 3, 2009·American Heart Journal·Campbell D JoynerSalim Yusuf
Feb 10, 2010·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Pascal VranckxPatrick W Serruys
Jun 15, 2011·Circulation·Roxana MehranHarvey White
Dec 15, 2012·American Heart Journal·Tomohisa TadaAdnan Kastrati
Nov 12, 2013·Journal of the American College of Cardiology·Tullio PalmeriniGregg W Stone
Mar 25, 2014·American Heart Journal·Ming Kai LamClemens von Birgelen
May 21, 2014·Cardiovascular Drugs and Therapy·Yanyu WangXiyan Shang
Sep 1, 2014·European Heart Journal·Stephan WindeckerAdam Witkowski
Sep 6, 2014·Lancet·Thomas PilgrimStephan Windecker
Apr 10, 2015·Circulation. Cardiovascular Interventions·Dean J KereiakesKeith D Dawkins
Jul 19, 2015·The American Journal of Cardiology·Alexis MatteauLaura Mauri
Sep 4, 2015·International Journal of Cardiology·Hongqiu GuJingan Yang
Oct 16, 2015·The New England Journal of Medicine·Philip UrbanUNKNOWN LEADERS FREE Investigators
Mar 12, 2016·JACC. Cardiovascular Interventions·Sara AriottiUNKNOWN ZEUS Investigators
Nov 4, 2016·Lancet·Clemens von BirgelenMarije M Löwik
Jan 23, 2017·JACC. Cardiovascular Interventions·Bent RaungaardUNKNOWN SORT OUT VI Investigators
Mar 11, 2017·JACC. Cardiovascular Interventions·Georges El-HayekHabib Samady
Aug 23, 2017·The American Journal of Cardiology·M Chadi AlraiesRon Waksman
Aug 24, 2017·Lancet·Robert A ByrneAdnan Kastrati
Aug 31, 2017·Lancet·David E KandzariUNKNOWN BIOFLOW V Investigators
Sep 10, 2017·European Heart Journal·Marco ValgimigliUNKNOWN ESC National Cardiac Societies
Nov 5, 2017·Scientific Reports·Pan LuXiaobo Mao
Nov 6, 2017·Lancet·Olivier VarenneUNKNOWN SENIOR investigators
Mar 10, 2018·JACC. Cardiovascular Interventions·Paolo ZoccaClemens von Birgelen
May 29, 2018·International Journal of Cardiology·Paolo ZoccaClemens von Birgelen